158 related articles for article (PubMed ID: 27286261)
1. Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.
Bansal N; Bosch A; Leibovitch B; Pereira L; Cubedo E; Yu J; Pierzchalski K; Jones JW; Fishel M; Kane M; Zelent A; Waxman S; Farias E
Oncotarget; 2016 Jul; 7(28):43689-43702. PubMed ID: 27286261
[TBL] [Abstract][Full Text] [Related]
2. The Sin3A/MAD1 Complex, through Its PAH2 Domain, Acts as a Second Repressor of Retinoic Acid Receptor Beta Expression in Breast Cancer Cells.
Dahiya NR; Leibovitch BA; Kadamb R; Bansal N; Waxman S
Cells; 2022 Mar; 11(7):. PubMed ID: 35406744
[TBL] [Abstract][Full Text] [Related]
3. Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells.
Kwon YJ; Leibovitch BA; Bansal N; Pereira L; Chung CY; Ariztia EV; Zelent A; Farias EF; Waxman S
Oncotarget; 2017 Oct; 8(51):88421-88436. PubMed ID: 29179446
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Kwon YJ; Petrie K; Leibovitch BA; Zeng L; Mezei M; Howell L; Gil V; Christova R; Bansal N; Yang S; Sharma R; Ariztia EV; Frankum J; Brough R; Sbirkov Y; Ashworth A; Lord CJ; Zelent A; Farias E; Zhou MM; Waxman S
Mol Cancer Ther; 2015 Aug; 14(8):1824-36. PubMed ID: 26078298
[TBL] [Abstract][Full Text] [Related]
5. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.
Farias EF; Petrie K; Leibovitch B; Murtagh J; Chornet MB; Schenk T; Zelent A; Waxman S
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11811-6. PubMed ID: 20547842
[TBL] [Abstract][Full Text] [Related]
6. Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.
Bansal N; Petrie K; Christova R; Chung CY; Leibovitch BA; Howell L; Gil V; Sbirkov Y; Lee E; Wexler J; Ariztia EV; Sharma R; Zhu J; Bernstein E; Zhou MM; Zelent A; Farias E; Waxman S
Oncotarget; 2015 Oct; 6(33):34087-105. PubMed ID: 26460951
[TBL] [Abstract][Full Text] [Related]
7. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
Lu Y; Bertran S; Samuels TA; Mira-y-Lopez R; Farias EF
Oncogene; 2010 Jun; 29(25):3665-76. PubMed ID: 20453882
[TBL] [Abstract][Full Text] [Related]
9. Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A-PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1.
Kadamb R; Leibovitch BA; Farias EF; Dahiya N; Suryawanshi H; Bansal N; Waxman S
Transl Oncol; 2022 Feb; 16():101320. PubMed ID: 34968869
[TBL] [Abstract][Full Text] [Related]
10. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
11. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
12. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H
J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
15. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
[TBL] [Abstract][Full Text] [Related]
16. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological characterization of Disila-AM80 (Disila-tamibarotene) and Disila-AM580, silicon analogues of the RARalpha-selective retinoid agonists AM80 (Tamibarotene) and AM580.
Tacke R; Müller V; Büttner MW; Lippert WP; Bertermann R; Daiss JO; Khanwalkar H; Furst A; Gaudon C; Gronemeyer H
ChemMedChem; 2009 Nov; 4(11):1797-802. PubMed ID: 19790202
[No Abstract] [Full Text] [Related]
19. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
20. Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene).
Nakazato T; Okudaira T; Ishikawa C; Nakama S; Sawada S; Tomita M; Uchihara JN; Taira N; Masuda M; Tanaka Y; Ohshiro K; Takasu N; Mori N
Cancer Sci; 2008 Nov; 99(11):2286-94. PubMed ID: 18771528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
